GLP-1 Medications: Could Weight Loss Treatments Actually Increase Dementia Risk?
New findings suggest GLP-1 medications may elevate dementia risk, challenging existing beliefs about obesity treatments.
Novo Nordisk
New Studies Reveal GLP-1 Drugs May Alter Dementia Risk—What You Need to Know
GLP-1 drugs may reduce dementia risk by 30%. Find out how these medications influence cognitive health and what this means for prevention.
SELECT Trial Reveals GLP-1 Medications Could Enhance Longevity Beyond Weight Loss
By Dr. Priya Nair, Health Technology Reviewer Last updated: May 14, 2026 SELECT Trial Reveals GLP-1 Medications Could Enhance Longevity Beyond Weight Loss In a remarkable finding from the SELECT trial, GLP-1 medications such as semaglutide have demonstrated a potential to recalibrate our understanding of longevity beyond mere weight loss. The trial discovered a striking … Read more
SELECT Trial Unveils GLP-1 Meds’ Hidden Power: Longevity Factor Exposed
Discover how the SELECT trial indicates that GLP-1 medications might enhance longevity beyond weight loss.
SELECT Trial Reveals GLP-1 Impact on Longevity Biology Beyond Weight Loss
Discover how GLP-1 medications reveal profound longevity insights that extend beyond weight loss and reshape preventive medicine.
SELECT Trial Data Reveals GLP-1 Medications Boost Longevity Beyond Weight Loss
Explore how SELECT trial data reveals GLP-1 medications’ potential in boosting longevity beyond just weight loss, with significant cardiovascular benefits.
SELECT Trial Reveals GLP-1 Drugs Could Extend Life Beyond Weight Loss
Discover how SELECT Trial data signals that GLP-1 drugs may impact longevity beyond weight loss, unveiling a $50 billion market opportunity.